BC Innovations | Oct 25, 2018
Distillery Therapeutics

Autoimmune disease

INDICATION: Inflammatory bowel disease (IBD) In vitro and mouse studies identified an isopropylcarboxamide-based Hsp90B1 inhibitor that could help treat ulcerative colitis (UC). Structure-based design, chemical synthesis and in vitro activity and binding assays of isopropylcarboxamide...
BC Innovations | Mar 7, 2018
Distillery Therapeutics


INDICATION: Solid tumors In vitro and cell culture studies identified Hsp90B1 inhibitors that could help treat solid tumors. Chemical synthesis, in vitro binding and cell-based assays of resorcinol analogs yielded a compound that inhibited Hsp90B1...
BC Week In Review | Feb 24, 2017
Clinical News

Prophage G-200: Ph II data

Agenus halted enrollment in an open-label, U.S. Phase II trial in about 165 patients with surgically resectable, recurrent GBM after a DSMB determined intradermal Prophage G-200 plus Avastin bevacizumab was unlikely to improve survival vs....
BC Week In Review | Jan 6, 2017
Clinical News

HS-410: Additional Ph I/II data

Data from 94 patients with intermediate- or high-risk non-muscle invasive bladder cancer who have undergone transurethral resection of bladder tumor in the Phase II portion of a double-blind, U.S. Phase I/II trial showed that both...
BC Innovations | Dec 22, 2016
Product R&D

Fever pace for Zika

In less than two years since emerging as a global threat, the Zika virus has prompted an unprecedented acceleration of public and private translational research that has already put three vaccine candidates in the clinic....
BC Week In Review | Oct 31, 2016
Company News

Heat Biologics, University of Miami deal

Heat Biologics and the university partnered to develop vaccines to treat Zika, HIV, West Nile, dengue and yellow fever virus infections based on Heat’s heat shock 90 kDa protein beta 1 ( Hsp90B1 ; GP96 ;...
BC Extra | Oct 25, 2016
Clinical News

Heat, UMiami seek to create fetal Zika vaccine

Heat Biologics Inc. (NASDAQ:HTBX) and the University of Miami said they are collaborating to develop vaccines targeting the Zika virus and other infectious diseases based on Heat's heat shock 90 kDa protein beta 1 ( Hsp90B1...
BC Week In Review | Oct 17, 2016
Company News

Heat Biologics, Adaptive Biotechnologies deal

Heat and Adaptive partnered to discover immune biomarkers for Heat’s immunotherapies, including HS-410 . The partners will use Adaptive’s immunoSEQ, an immune profiling assay that identifies T and B cell receptors. HS-410 is in Phase II...
BC Week In Review | Sep 19, 2016
Clinical News

Viagenpumatucel-L: Phase Ib/II resumed

Heat Biologics resumed enrollment in the Phase Ib portion of the open-label, U.S. Phase Ib/II DURGA trial evaluating once-weekly injections of 1x10 7 cells of HS-110 for 18 weeks plus Opdivo nivolumab. The decision was...
BioCentury | Jul 11, 2016

Shedding red

Steve Edelson, Senior Editor   Brexit nearly wiped out what looked to be a rebound quarter for biotech. Only two market cap segments finished in positive territory, and smaller companies continued to get pounded. Big...
Items per page:
1 - 10 of 59